Roche's experimental lung cancer drug beat two rivals in a pivotal trial
Median overall survival reached 17.7 months with divarasib versus 12.0 months for sotorasib or adagrasib in a 338-patient phase III study
We haven't written up this one. Quartz has the full story — the link below goes straight to it.